Carbidopa
"Carbidopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.
Descriptor ID |
D002230
|
MeSH Number(s) |
D02.092.311.200.538.200 D02.442.200
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Carbidopa".
Below are MeSH descriptors whose meaning is more specific than "Carbidopa".
This graph shows the total number of publications written about "Carbidopa" by people in this website by year, and whether "Carbidopa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 1 | 0 | 1 | 2017 | 0 | 1 | 1 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbidopa" by people in Profiles.
-
Russo AM, Payet JM, Kent S, Lesku JA, Lowry CA, Hale MW. Acute treatment with 5-hydroxytryptophan increases social approach behaviour but does not activate serotonergic neurons in the dorsal raphe nucleus in juvenile male BALB/c mice: A model of human disorders with deficits of sociability. J Psychopharmacol. 2022 07; 36(7):806-818.
-
Phillips A, Hoyte FCL, Leung DYM. Dystonia as an unusual presentation of systemic mastocytosis: Possible link between histamine release and movement disorders. J Allergy Clin Immunol Pract. 2018 Jan - Feb; 6(1):269-271.e1.
-
Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother. 2015; 16(18):2807-17.
-
Fan Z, Greenwood R, Felix AC, Shiloh-Malawsky Y, Tennison M, Roche M, Crooks K, Weck K, Wilhelmsen K, Berg J, Evans J. GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia. J Neurol. 2014 Mar; 261(3):622-4.
-
Seeberger LC, Hauser RA. Levodopa/carbidopa/entacapone in Parkinson's disease. Expert Rev Neurother. 2009 Jul; 9(7):929-40.
-
Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006 Oct; 21(10):1741-4.
-
Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000 Mar-Apr; 23(2):75-81.
-
Echizen H, Freed CR. Long-term infusion of L-5-hydroxytryptophan increases brain serotonin turnover and decreases blood pressure in normotensive rats. J Pharmacol Exp Ther. 1982 Mar; 220(3):579-84.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|